DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Guanfacine (Guanfacine Hydrochloride) - Summary



Guanfacine hydrochloride is a centrally acting antihypertensive with α -adrenoceptor agonist properties in tablet form for oral administration.

Guanfacine hydrochloride tablets are indicated in the management of hypertension. Guanfacine may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.

See all Guanfacine indications & dosage >>


Media Articles Related to Guanfacine

Shire receives European approval for INTUNIV as a non-stimulant ADHD treatment for children and adolescents
Source: ADHD / ADD News From Medical News Today [2015.09.21]
Shire has announced that the European Commission granted Marketing Authorisation for once-daily, non-stimulant INTUNIV® (guanfacine hydrochloride prolonged release tablets) for the treatment of...

Targeted Therapies May Ease Severe Pulmonary Hypertension
Source: Medscape Critical Care Headlines [2015.09.29]
A new analysis has spotted a mortality reduction in patients with severe pulmonary hypertension caused by lung disease, but doubts remain.
Medscape Medical News

Targeting hypertension by helping pharmacists deliver enhanced patient care
Source: Hypertension News From Medical News Today [2015.09.21]
Patients with high blood pressure are benefiting from the expanded role played by pharmacists in Alberta, according to a new study from the University of Alberta's Faculty of Medicine & Dentistry.

Hypertension drug reduces inflammation from traumatic brain injury
Source: Hypertension News From Medical News Today [2015.09.21]
A new study on the processes causing inflammation after a TBI identifies a protein produced in the liver that can be blocked using a drug for hypertension.

New imaging technique reveals early brain damage caused by hypertension
Source: Hypertension News From Medical News Today [2015.09.18]
Researchers have found that a new imaging technique known as diffusion tensor imaging can show when high blood pressure causes early damage to neural pathways in the brain.

more news >>

Published Studies Related to Guanfacine

Efficacy of guanfacine extended release assessed during the morning, afternoon, and evening using a modified Conners' Parent Rating Scale-revised: Short Form. [2014]
attention-deficit/hyperactivity disorder (ADHD)... CONCLUSIONS: These results provide further support for the demonstrated efficacy

Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. [2013]
CONCLUSIONS: GXR administered either in the morning or evening was associated

Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia. [2013]
induced craving and have reduced opiate relapse in small clinical trials... CONCLUSIONS: Adding guanfacine to naltrexone did not improve treatment retention

Guanfacine extended-release: in attention deficit hyperactivity disorder. [2010.09.10]
Guanfacine, an alpha(2A)-adrenoceptor agonist, is available in the US as an extended-release (ER) tablet for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents (aged 6-17 years). In two large, randomized, double-blind, placebo-controlled trials of 8 and 9 weeks' duration, guanfacine ER (1-4 mg once daily) was effective in reducing the symptoms of ADHD (hyperactivity, impulsivity and inattention) in children and adolescents...

Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. [2010.09.01]
CONCLUSIONS: In this population of children aged 6-12 years with ADHD and the presence of oppositional symptoms, significant reductions in CPRS-R:L oppositional subscale and ADHD-RS-IV total scores were observed with guanfacine XR treatment compared with placebo. Treatment with guanfacine XR at optimized doses was associated with mostly mild or moderate TEAEs. The findings of this study support the efficacy of guanfacine XR in the treatment of children with ADHD and the presence of oppositional symptoms. Clinical Trial Registration Number: NCT00367835.

more studies >>

Clinical Trials Related to Guanfacine

PK/PD Comparison of Guanfacine ER and IR [Active, not recruiting]
Evaluate whether a 4mg/day or 6/mg day dose of extended-release guanfacine produces pharmacokinetic/dynamic (PK/PD) properties similar to 3mg/day immediate release guanfacine.

Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65). [Completed]
This is considered an investigator-initiated clinical research trial, which means that your study doctor is researching a particular medication (in this case a medication that is currently FDA- approved) for the treatment of AD/HD in individuals ages 6-17. The medication is guanfacine hydrochloride. The hypothesis is that this medication could be used in adults with Attention Deficit/Hyperactivity Disorder who have not received satisfactory results with their current stimulant ADHD medication. The study drug is investigational for use in adults. Investigational means it has not been approved by the U. S. Food and Drug Administration (FDA) for use in adults.

Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence [Completed]
The purpose of this study is to determine whether guanfacine represents a tolerable, potentially effective pharmacotherapy option for cannabis dependence. Interested in seeing whether guanfacine treatment reduces marijuana consumption, withdrawal symptoms, and craving as compared to baseline.

Does Guanfacine Attenuate Stress-Induced Drinking? [Recruiting]
Evaluating the effect of guanfacine on alcohol consumption. The investigators hypothesize that guanfacine versus placebo will decrease the number of drinks consumed during the 2-hour self-administration period across stress and neutral/relaxing conditions.

Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH) [Recruiting]
Combination of guanfacine with opioid medication as a standard treatment for chronic pain.

more trials >>

Reports of Suspected Guanfacine Side Effects

Confusional State (3)Dyspepsia (3)Coordination Abnormal (3)Swelling Face (3)Swollen Tongue (3)Blood Pressure Decreased (3)Complex Partial Seizures (3)Sedation (2)Formication (2)LIP Swelling (1)more >>

Page last updated: 2015-09-29

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015